The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer

Emma L. Barber, Emese Zsiros, John R. Lurain, Alfred Rademaker, Julian C. Schink, Nikki L. Neubauer

Research output: Contribution to journal › Review article › peer-review

37 Scopus citations

Fingerprint

Dive into the research topics of 'The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer'. Together they form a unique fingerprint.

Medicine and Dentistry

INIS